PRPO News and Press, Precipio Inc. From 08/17/23

2023-08-17 18:32:03 ET Precipio, Inc. (PRPO) Q2 2023 Earnings Conference Call August 17, 2023, 05:00 PM ET Company Participants Ilan Danieli - CEO Conference Call Participants Presentation Operator Welcome to the Precipio Second Quarter 2023 S...

NEW HAVEN, Conn., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q2-2023 corporate update call on August 17 th at 5:00 PM ET. The call will include updates on all of the company’s current core businesse...

2023-08-08 11:14:51 ET Specialty cancer diagnostics company Precipio ( NASDAQ: PRPO ) on Tuesday announced the launch of its new quantitative BCR-ABL 2.0 panel. Precipio's HemeScreen BCR-ABL 2.0 assay stands out as the sole market panel offering quantitative coverage...

NEW HAVEN, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces the launch of its new quantitative BCR-ABL 2.0 panel, with features making it the most innovative panel of its kind on the market. For more informatio...

NEW HAVEN, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces significant reductions in its cash-burn. For the six months ended June 30, 2023, Precipio is projected to report cash burn (excluding financing procee...

NEW HAVEN, Conn., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that Q2-2023 revenues have increased to $3.5M in Q2-2023 from $2.8M in Q1-2023, an increase of 25% QoQ. The following factors contribute to the ...

NEW HAVEN, Conn., June 14, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. leveraged its proprietary HemeScreen Cytopenia panel as part of the diagnostic process for molecular identification of driver mutations in a patient with a history of transfusion-de...

NEW HAVEN, Conn., June 13, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that it has entered into a collaboration agreement with a NY-based academic healthcare institution to jointly develop a panel for Glioblastoma (GBM), ...

2023-06-08 08:48:54 ET Precipio ( NASDAQ: PRPO ) has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 4.13M shares of the Co.’s common stock and pre-funded warrants to purchase 0.32M shares in a registered dir...

NEW HAVEN, Conn., June 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , today announced it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 4,125,000 shares of the Com...